SCHEMBL7872399

SCHEMBL7872399

O=C(O)c1cccc2nc(-c3ccccc3)cn12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 1/20 0.51
NTRK1 P04629 1/20 0.49
IGF1R P08069 1/20 0.49
FGFR1 P11362 1/20 0.49
LTK P29376 1/20 0.49
MAP2K2 P36507 1/20 0.49
MAPK9 P45984 1/20 0.49
RPS6KA3 P51812 1/20 0.49
PRKX P51817 1/20 0.49
PRKCQ Q04759 1/20 0.49
TNK2 Q07912 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49
TGFBR1 P36897 1/20 0.45
ALDH1A1 P00352 8/20 0.44
KDM4E B2RXH2 7/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
RAB9A P51151 5/20 0.43
NPC1 O15118 4/20 0.43
HPGD P15428 2/20 0.43
POLB P06746 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8866970 0.84 ALDH1A3 (0.50) TGFBR1RAB9ANPC1ALDH1A3ADORA2A
SCHEMBL18038359 0.84 ALDH1A1 (0.53) MAP2K1NTRK1IGF1RFGFR1LTK
Bromide SCHEMBL8865936 0.83 ALDH1A3 (0.49) TGFBR1RAB9ANPC1ALDH1A3ADORA2A
SCHEMBL9753622 0.78 PTGS1 (0.53) TGFBR1KDM4ERAB9ANPC1PTGS1
SCHEMBL21816403 0.77 TGFBR1 (0.44) TGFBR1ALDH1A1KDM4ESMN1; SMN2RAB9A
SCHEMBL8605700 0.76 TGFBR1 (0.35) MAP2K1TGFBR1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL1104800 0.75 MAPT (0.61) MAP2K1NTRK1IGF1RFGFR1LTK
SCHEMBL29080578 0.75 FGFR1 (0.53) MAP2K1NTRK1IGF1RFGFR1LTK
SCHEMBL28842472 0.75 FGFR1 (0.53) MAP2K1NTRK1IGF1RFGFR1LTK
SCHEMBL29080571 0.75 CLK4 (0.53) MAP2K1NTRK1IGF1RFGFR1LTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010051631-A1 Tricyclic compounds, their production and use TAKATANI MUNEO (JP) 2001-12-13 US disclosed
US-6251905-B1 Tricyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-06-26 US disclosed
US-5958942-A HAVING EXCELLENT PDGF-INHIBITING ACTIVITIES, ANTIHYPERTENSIVE ACTIVITIES, ACTIVITIES OF AMELIORATING RENAL DISEASES AND ACTIVITIES OF LOWERING LIPID LEVEL. TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-09-28 US disclosed
EP-0771319-A1 TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1997-05-07 EP disclosed
WO-1996002542-A1 TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051631-A1 Tricyclic compounds, their production and use PDGFA, HGF, REN MAP2K1 3342/4885NTRK1 819/4885IGF1R 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.